Quarterly Reports, Licensing Agreements, and Clinical Data - Research Report on Theravance, Dendreon, ImmunoGen, Compugen, and Acorda

NEW YORK, October 22, 2013 /PRNewswire/ --

Editor Note: For more information about this release, please scroll to bottom.

Today, Analysts' Corner announced new research reports highlighting Theravance Inc. (NASDAQ: THRX), Dendreon Corp. (NYSE: DNDN), ImmunoGen, Inc. (NASDAQ: IMGN), Compugen Ltd. (NASDAQ: CGEN), and Acorda Therapeutics, Inc. (NASDAQ: ACOR). Today's readers may access these reports free of charge - including full price targets, industry analysis and analyst ratings - via the links below.

Theravance Inc. Research Report

On October 10, 2013, Theravance Inc. (Theravance) announced that it will release its Q3 2013 results after market close on Thursday, October 24, 2013. Theravance reported that the Q3 2013 conference call will be held on the same day at 5:00 p.m. EDT, and is accessible through its website. The Company further informed that a replay of the conference call will be available on its website for 30 days until November 23, 2013, whereas an audio replay that will be available until 11:59 p.m. EDT on October 31, 2013. The Full Research Report on Theravance Inc. - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at: [http://www.AnalystsCorner.com/r/full_research_report/fa70_THRX]

--

Dendreon Corp. Research Report

On October 7, 2013, Dendreon Corp. (Dendreon) announced that the management will host its Q3 2013 conference call on Tuesday, November 12, 2013 at 9:00 a.m. EST / 6:00 a.m. PST. The Company reported that interested parties may access the call by visiting its Investor Relations website or by using the designated dial-in lines. Dendreon further informed that a replay will be available on its website for 90 days. The Company also announced that its management will present at the Credit Suisse 2013 Healthcare Conference in Scottsdale, AZ, on November 13 at 3:00 p.m. MST, as well as the Lazard Capital Markets 10th Annual Healthcare Conference in New York City on November 20 at 8:30 a.m. EST. The Full Research Report on Dendreon Corp. - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at: [http://www.AnalystsCorner.com/r/full_research_report/de0c_DNDN]

--

ImmunoGen, Inc. Research Report

On October 11, 2013, ImmunoGen, Inc. (ImmunoGen) announced that Novartis has licensed the exclusive right to use the Company's ADC technology to develop anticancer therapeutics to an undisclosed target. According to ImmunoGen, this is the second license to be taken by Novartis under a 2010 agreement between the Companies. The Company reported that under this arrangement, it receives an upfront payment for each license as well as milestone payments potentially totaling approximately $200 million plus royalties on the sales of any resulting products. The Full Research Report on ImmunoGen, Inc. - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at: [http://www.AnalystsCorner.com/r/full_research_report/11c8_IMGN]

--

Compugen Ltd. Research Report

On October 9, 2013, Compugen Ltd. (Compugen) announced today that CGEN-15001, an Fc fusion protein drug candidate derived from a novel immune checkpoint protein discovered by Compugen, has been shown to be highly efficient in preventing the development of disease in a well-accepted animal model of autoimmune type I diabetes, known also as juvenile diabetes. Anat Cohen-Dayag, Ph.D., Compugen's President and CEO, stated, "The results being reported today show that this Fc fusion protein also has a remarkable effect in a well-accepted disease model of type I diabetes, a severe, life-long disease with no current cure. These findings highlight the potential of CGEN-15001 to treat multiple autoimmune conditions and the promise of developing new effective immune modulating therapeutic drug candidates based on Compugen's discovery platforms." The Full Research Report on Compugen Ltd. - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at: [http://www.AnalystsCorner.com/r/full_research_report/d15a_CGEN]

--

Acorda Therapeutics, Inc. Research Report

On October 14, 2013, Acorda Therapeutics, Inc. (Acorda) announced data from a Phase 2 proof-of-concept study of dalfampridine extended release tablets, 10 mg (dalfampridine-ER) in people with post-stroke deficits. According to the Company, the study showed that treatment with dalfampridine-ER was well-tolerated and improved walking, as measured by the Timed 25-Foot Walk test (T25FW). Enrique Carrazana, M.D., Acorda's Chief Medical Officer, said, "Based on the strength of the data, we are planning a larger clinical trial to further assess dalfampridine's safety and tolerability, and potential effect on walking impairment in people with post-stroke deficits." The Full Research Report on Acorda Therapeutics, Inc. - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at: [http://www.AnalystsCorner.com/r/full_research_report/d67c_ACOR]

----

EDITOR NOTES:

COMPLIANCE PROCEDURE

Content is researched, written and reviewed on a best-effort basis. This document, article or report is prepared and authored by Equity News Network. An outsourced research services provider represented by Ananya Ghosh, CFA, has only reviewed the information provided by Equity News Network in this article or report according to the Procedures outlined by Equity News Network. Equity News Network is not entitled to veto or interfere in the application of such procedures by the outsourced provider to the articles, documents or reports, as the case may be.

NOT FINANCIAL ADVICE

Equity News Network makes no warranty, expressed or implied, as to the accuracy or completeness or fitness for a purpose (investment or otherwise), of the information provided in this document. This information is not to be construed as personal financial advice. Readers are encouraged to consult their personal financial advisor before making any decisions to buy, sell or hold any securities mentioned herein.

NO WARRANTY OR LIABILITY ASSUMED

Equity News Network is not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted by Equity News Network whatsoever for any direct, indirect or consequential loss arising from the use of this document. Equity News Network expressly disclaims any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Equity News Network does not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.

CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.

AnalystsCorner.com

SOURCE Analysts' Corner